Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Syndrome Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DYRK1B drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Target Protein | DYRK1B Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Kinase Domain Active. Sequence Verified. |
View DYRK1B Products |
| Gene Delivery | DYRK1B Lentivirus Particles Full-length ORF for stable cell line construction. CMV promoter, Puromycin selection. |
View DYRK1B Products |
| Benchmark Ab | Anti-DYRK1B Control Antibody Recombinant rabbit monoclonal for Western/IP control. |
View DYRK1B Products |
| Validator | DYRK1B siRNA Set (3 unique targets) For knockdown verification and specificity confirmation. |
View DYRK1B Products |
| Related Target A | DYRK1A Critical off-target homolog for selectivity screening (CNS safety). |
View DYRK1A Products |
| Related Target B | CDK4 Synergistic pathway target for cell cycle regulation and G1 arrest bypass. |
View CDK4 Products |
| Related Target C | DYRK1B (L245F Gatekeeper Mutant) Drug resistance model for next-gen inhibitor design. |
View DYRK1B Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Selectivity Screening (vs DYRK1A) | Human DYRK1B & DYRK1A proteins available as distinct, sequence-verified constructs for parallel enzymatic assays; high purity (>95%) recombinant kinase, Endotoxin Controlled. |
| High-Throughput Inhibitor Screening | High Purity (>95%) recombinant kinase, Endotoxin Controlled, and Active Kinase Domain for biochemical assays. |
| Drug Resistance Profiling | L245F Gatekeeper Mutant protein (Theoretical MW verified) for resistance mechanism studies. |
| Cellular Target Engagement | HEK293-expressed Lentivirus for stable overexpression; Endotoxin controlled (<0.1 EU/ml). |
| Lack of Controls | Clinical Benchmark Antibodies included for expression validation. |
| False Positives in Cell Assays | Validated siRNA included for specificity checks. |
| Mechanism of Action Validation | Active Kinase Domain (aa 1-557) with ATP-binding site intact for biochemical assays. |
Live DYRK1B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The DYRK1B (MIRK) kinase is emerging as a bifunctional node in cancer metabolism and myogenic differentiation. As a key regulator of the G0/G1-S cell cycle transition, DYRK1B is a prime target for overcoming resistance in solid tumors and addressing metabolic disorders. Unlike its paralog DYRK1A—where inhibition raises acute neurodevelopmental safety flags—DYRK1B-selective targeting offers a therapeutic window for solid tumors (pancreatic, ovarian, colorectal) and muscle-wasting disorders. The current pipeline is dominated by ATP-competitive small molecules, with a strategic pivot toward allosteric modulators and proteolysis-targeting chimeras (PROTACs) to circumvent gatekeeper resistance mutations. As first-generation therapies reach the clinic, the next wave of R&D is targeting ultra-selective inhibitors that avoid DYRK1A-mediated off-target neural toxicities and exploring combination therapies with traditional cell cycle inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Kinase Inhibitor (Type I/II) | Various Biotech / Pharma; Academic Consortia | Solid Tumors (Pancreatic, Ovarian, Colorectal), Metabolic Syndrome | Selectivity Assay (Need High-Purity DYRK1B and DYRK1A proteins) |
| Targeted Protein Degrader (PROTAC) | Emerging Biotech | Refractory Solid Tumors | Degradation Assays (Need Lentivirus for cell-based ternary complex) |
| Allosteric Inhibitors | Early Discovery | Metabolic Syndrome | Conformational Binding Assay (Full-length protein required) |
| Combination Therapy (with CDK4/6i) | Academic / Translational consortia | Advanced Breast Cancer | Pathway Validation (Need complete related target toolkit including CDK4) |